Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001997151 | SCV002237333 | pathogenic | not provided | 2022-05-06 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with SEC63-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Val398Thrfs*4) in the SEC63 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SEC63 are known to be pathogenic (PMID: 20095989, 28375157). |
Fulgent Genetics, |
RCV002497853 | SCV002805411 | likely pathogenic | Polycystic liver disease 2 | 2021-09-23 | criteria provided, single submitter | clinical testing |